GlassScriptPhysician profile
Ernest Tsao
NPI 1790981256
$4,323.09
in general payments reported to CMS, 2019-2025
31 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $277 · 2021: $462 · 2022: $688 · 2023: $779 · 2024: $671 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975 · Education: $14.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.81 |
| Education | $14.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,147.50 | 2019-2025 | Trulance, Relistor, Xifaxan |
| Abbvie INC. | $773.48 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $668.63 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $404.65 | 2019-2025 | Tremfya, Stelara |
| Boston Scientific Corporation | $161.75 | 2019-2024 | |
| Ardelyx, INC. | $152.80 | 2022-2025 | Ibsrela |
| Pfizer INC. | $117.53 | 2019-2025 | |
| Celltrion USA INC. | $92.90 | 2024-2025 | Vegzelma, Zymfentra |
| Celgene Corporation | $82.77 | 2022-2023 | Zeposia |
| Gilead Sciences, INC. | $80.98 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.48 | 2019-2021 | |
| Qol Medical, LLC | $68.21 | 2019-2023 | Sucraid |
| Genzyme Corporation | $51.65 | 2025 | |
| Ferring Pharmaceuticals INC. | $48.78 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $44.83 | 2020-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $36.15 | 2023-2025 | Dupixent |
| Ucb, INC. | $34.05 | 2019 | |
| Madrigal Pharmaceuticals | $29.80 | 2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $28.79 | 2020 | |
| Fresenius Kabi USA, LLC | $28.34 | 2023 | Idacio |
| Allergan, INC. | $22.76 | 2019 | |
| Redhill Biopharma INC. | $20.44 | 2022 | |
| Shionogi INC | $18.46 | 2019 | |
| Daiichi Sankyo INC. | $18.24 | 2019 | |
| Organon LLC | $18.15 | 2023 | Hadlima, Renflexis |
| Alnylam Pharmaceuticals INC. | $17.70 | 2024 | Givlaari |
| Shire North American Group INC | $17.31 | 2019 | |
| Aimmune Therapeutics, INC. | $16.82 | 2025 | Zenpep |
| Phathom Pharmaceuticals, INC. | $16.14 | 2025 | Voquezna |
| Capsovision, INC. | $15.58 | 2024 | Capsocam Plus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.42 | 2023 | Cyltezo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernest Tsao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.